# A Study of YL202 in Selected Patients With Advanced Solid Tumors

> **NCT06107686** · PHASE2 · RECRUITING · sponsor: **MediLink Therapeutics (Suzhou) Co., Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- NSCLC
- Breast Cancer
- HNSCC
- Locally Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** YL202 should be intravenously infused

## Key facts

- **NCT ID:** NCT06107686
- **Lead sponsor:** MediLink Therapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-15
- **Primary completion:** 2026-11
- **Final completion:** 2028-11
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06107686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06107686, "A Study of YL202 in Selected Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06107686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*